4.8 Article

Next-Generation Manufacturing Protocols Enriching TSCMCAR T Cells Can Overcome Disease-Specific T Cell Defects in Cancer Patients

Journal

FRONTIERS IN IMMUNOLOGY
Volume 11, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2020.01217

Keywords

CAR T; CAR T cell manufacturing; CAR T cell fitness; CAR design; patient samples; B-ALL and PDAC

Categories

Funding

  1. European Union's Horizon 2020 Research and Innovation Program [667980]
  2. Italian Ministry of Health [GR-2013-02359212]
  3. Italian Ministry of Health and Alliance Against Cancer (Ricerca Corrente CAR T project) [RCR-2019-23669115]
  4. Italian Ministry of University and Research [MIUR-PRIN 2017WC8499_002]
  5. H2020 Societal Challenges Programme [667980] Funding Source: H2020 Societal Challenges Programme

Ask authors/readers for more resources

Chimeric antigen receptor (CAR) T cell expansion and persistence emerged as key efficacy determinants in cancer patients. These features are typical of early-memory T cells, which can be enriched with specific manufacturing procedures, providing signal one and signal two in the proper steric conformation and in the presence of homeostatic cytokines. In this project, we exploited our expertise with paramagnetic beads and IL-7/IL-15 to develop an optimized protocol for CAR T cell production based on reagents, including a polymeric nanomatrix, which are compatible with automated manufacturingviathe CliniMACS Prodigy. We found that both procedures generate similar CAR T cell products, highly enriched of stem cell memory T cells (T-SCM) and equally effective in counteracting tumor growth in xenograft mouse models. Most importantly, the optimized protocol was able to expand CAR T(SCM)from B-cell acute lymphoblastic leukemia (B-ALL) patients, which in origin were highly enriched of late-memory and exhausted T cells. Notably, CAR T cells derived from B-ALL patients proved to be as efficient as healthy donor-derived CAR T cells in mediating profound and prolonged anti-tumor responses in xenograft mouse models. On the contrary, the protocol failed to expand fully functional CAR T(SCM)from patients with pancreatic ductal adenocarcinoma, suggesting that patient-specific factors may profoundly affect intrinsic T cell quality. Finally, by retrospective analysis ofin vivodata, we observed that the proportion of T(SCM)in the final CAR T cell product positively correlated within vivoexpansion, which in turn proved to be crucial for achieving long-term remissions. Collectively, our data indicate that next-generation manufacturing protocols can overcome initial T cell defects, resulting in T-SCM-enriched CAR T cell products qualitatively equivalent to the ones generated from healthy donors. However, this positive effect may be decreased in specific conditions, for which the development of further improved protocols and novel strategies might be highly beneficial.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available